JPMorgan Chase & Co. Acquires 8,533 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

JPMorgan Chase & Co. grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 272,255 shares of the company’s stock after purchasing an additional 8,533 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.55% of Prestige Consumer Healthcare worth $19,630,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Quest Partners LLC increased its holdings in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the period. nVerses Capital LLC raised its position in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares in the last quarter. Huntington National Bank lifted its stake in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its position in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Up 0.9 %

NYSE:PBH opened at $74.45 on Friday. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a twelve month low of $58.22 and a twelve month high of $86.36. The company has a market cap of $3.68 billion, a PE ratio of 18.11, a P/E/G ratio of 2.32 and a beta of 0.51. The company’s 50 day moving average is $80.56 and its two-hundred day moving average is $74.17.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same period in the prior year, the firm earned $1.07 EPS. The firm’s revenue was down .9% on a year-over-year basis. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Analyst Upgrades and Downgrades

PBH has been the subject of a number of recent research reports. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 over the last three months. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.